Monoclonal antibodies for anti-infective therapy

1Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sera of animal origin and hyperimmunoglobulins have dominated serum therapy for a century. Although numerous monoclonal antibodies (MABs) have been developed since the end of the 1980s, particularly for the treatment of immunological and oncological diseases, it will take 20 years before the first anti-infective MAB is approved in the European Union. Interestingly, to combat the COVID-19 pandemic, numerous MABs, which are approved in particular for immunological indications, are currently being used to treat the consequences of SARS-CoV‑2 infection, such as pneumonia or hyperimmune reactions. The approved monoclonal antibodies for the treatment of infectious diseases are presented here. In addition, an overview of the current developments, in particular in the treatment of SARS-CoV‑2 infection, is provided.

Cite

CITATION STYLE

APA

Klug, B., Schnierle, B., & Trebesch, I. (2020, November 1). Monoclonal antibodies for anti-infective therapy. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00103-020-03229-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free